Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 317

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 317
---
 from related parties at the end of 2023. We have incurred losses and generated negative cash flows from operations since inception in 2015. To date we have not generated revenues, and we do not expect to generate any significant revenue from the sale of our product candidates in the near future. We expect to generate losses for the foreseeable future, and these losses could increase as we continue product development until we successfully achieve regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all the risks pertinent to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We anticipate that we will need substantial additional funding in connection with our continuing operations. If we need to raise additional capital to fund our operations and complete our ongoing and planned clinical studies, funding may not be available to us on acceptable terms, or at all. As of June 30, 2024, our cash and cash equivalents was $0.6 million. Our existing cash and cash equivalents and access to existing financing arrangements will not be sufficient to fund operations for a period of one year as of June 30, 2024. We expect to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support our planned operating activities through profitability. We are actively exploring a range of options to raise funds, including strategic partnerships, out -licensing, or divestment of assets of NLS, and other future strategic actions. By October 10, 2024, we have completed a private financing round, debt conversion and forgiveness, vendor buy -out, and have identified a merger opportunity. Our future viability depends on our ability to extend payment terms with third -partycreditors until additional funds have been raised. 170 Capital Resources and Liquidity We remain committed to strengthening our financial position and continue to evaluate various options to secure additional capital to support our long -termobjectives. These options may include strategic equity offerings, non -dilutivefinancing alternatives, debt restructuring, and partnerships that align with our R&D priorities. Our goal is to access capital in a disciplined manner, minimizing shareholder dilution while ensuring the necessary resources to advance our key development programs. Following June30, 2024, we implemented a comprehensive restructuring plan designed to enhance financial flexibility, streamline operations, and support our long -termgrowth. This plan includes: 1.Securing Additional Financing — We are actively pursuing funding opportunities to